EC Orthopaedics

Review Article Volume 16 Issue 5 - 2025

The Secrets of Clodronate: An Old Drug with a New Soul

Rosini Sergio1, Rosini Stefano2, Molfetta Francesco3 and Molfetta Luigi4*

1Biomaterial Research Center, Livorno, Italy

2Smile-Restyle, Livorno, Italy

3DINOGMI Department, School of Medical and Pharmaceutical Sciences, University of Genoa, Genoa, Italy

4DISC Department, School of Medical and Pharmaceutical Sciences, Research Center of Osteoporosis and Osteoarticular Pathologies, University of Genoa, Genoa, Italy

*Corresponding Author: Molfetta Luigi, DISC Department, School of Medical and Pharmaceutical Sciences, Research Center of Osteoporosis and Osteoarticular Pathologies, University of Genoa, Genoa, Italy.
Received: August 01, 2025; Published: September 18, 2025




Clodronate belongs to a class of drugs (bisphosphonates - BPs) that began to be studied in the late 1960s due to their high affinity for bone hydroxyapatite, to which they bind stably while inhibiting osteoclastic bone resorption. Although BPs share similar chemical structures, they exhibit markedly different pharmacodynamic behaviors and systemic tolerability profiles, both in terms of their primary activity and safety. Studies conducted over the years on these interesting compounds-characterized by poor oral absorption and rapid renal excretion without undergoing metabolic transformation-have revealed their potential applications in various pathological conditions beyond their main anti-osteoclastic action. In this regard, Clodronate stands out among bisphosphonates for its broad spectrum of demonstrated activities and excellent tolerability.

 Keywords: Clodronate; Bisphosphonate; VNUT; Purinergic Receptors; Immunity

  1. McCloskey EV., et al. “Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study”. Journal of Bone and Mineral Research 1 (2007): 135-141.
  2. Russell RGG., et al. “Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy”. Osteoporosis International 6 (2008): 733-759.
  3. Manolagas SC and Parfitt AM. “What old means to bone”. Trends in Endocrinology and Metabolism 6 (2010): 369-374.
  4. H L Benford., et al. “Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs”. Molecular Pharmacology 1 (1999): 131-140.
  5. Petri P Lehenkari., et al. “Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite”. Molecular Pharmacology 5 (2002): 1255-1262.
  6. Adami S., et al. “The acute-phase response after bisphosphonate administration”. Calcified Tissue International 6 (1987): 326-331.
  7. Peter D Papapetrou. “Bisphosphonate-associated adverse events”. Hormones (Athens)2 (2009): 96-110.
  8. Okada S., et al. “Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice”. Tohoku Journal of Experimental Medicine 2 (2013): 145-158.
  9. Naviaux RK. “Metabolic features of the cell danger response”. Mitochondrion 16 (2014): 7-17.
  10. Ryan C Riddle and Henry J Donahue. “From streaming-potentials to shear stress: 25 years of bone cell mechanotransduction”. Journal of Orthopaedic Research2 (2009): 143-280.
  11. Ryan C Riddle., et al. “ATP release mediates fluid flow-induced proliferation of human bone marrow stromal cells”. Journal of Bone and Mineral Research 4 (2007): 589-600.
  12. Riekje Winzer., et al. “Purinergic enzymes on extracellular vesicles: immune modulation on the go”. Frontiers in Immunology 15 (2024): 1362996.
  13. Xiaosong Yi., et al. “Adenosine receptors enhance the ATP-induced odontoblastic differentiation of human dental pulp cells”. Biochemical and Biophysical Research Communications 3 (2018): 850-856.
  14. Moriyama Y., et al. “Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of purinergic signaling”. Purinergic Signalling 3 (2017): 387-404.
  15. L A Bankston and G Guidotti. “Characterization of ATP transport into chromaffin granule ghosts. Synergy of ATP and serotonin accumulation in chromaffin granule ghosts”. Journal of Biological Chemistry 29 (1996): 17132-17138.
  16. Yuri Kato., et al. “Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain”. Proceedings of the National Academy of Sciences of the United States of America 31 (2017): E6297-E6305.
  17. Moriyama Y and Nomura M. “Clodronate: A vesicular ATP release blocker”. Trends in Pharmacological Sciences 1 (2018): 13-23.
  18. Siyoung Kim., et al. “Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone”. European Journal of Pharmacology 1-3 (2013): 14-22.
  19. Tufan Mert., et al. “Anti-inflammatory properties of Liposome-encapsulated clodronate or Anti-Ly6G can be modulated by peripheral or central inflammatory markers in carrageenan-induced inflammation model”. Inflammopharmacology3 (2019): 603-612.
  20. Tonia L Vincent. “Peripheral pain mechanisms in osteoarthritis”. Pain 1 (2020): S138-S146.
  21. Yuika Harada., et al. “Vesicular nucleotide transporter mediates ATP release and migration in neutrophils”. Journal of Biological Chemistry 10 (2018): 3770-3779.
  22. Mass E. “The stunning clodronate”. Journal of Experimental Medicine 6 (2023): e20230339.
  23. Culemann S., et al. “Stunning of neutrophils accounts for the anti-inflammatory effects of clodronate liposomes”. Journal of Experimental Medicine 6 (2023): e20220525.
  24. Adami S., et al. “Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton”. Journal of Urology 6 (1985): 1152-1154.
  25. A H Paterson., et al. “Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer”. Canadian Journal of Oncology 1 (1995): 54-57.
  26. A Jung., et al. “Use of dichloromethylene diphosphonate in metastatic bone disease”. New England Journal of Medicine 25 (1983): 1499-1501.
  27. Adami S., et al. “Bisphosphonate therapy of reflex sympathetic dystrophy syndrome”. Annals of the Rheumatic Diseases 3 (1997): 201-204.
  28. Varenna M., et al. “Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study”. Journal of Rheumatology 6 (2000): 1477-1483.
  29. Bruno Frediani., et al. “Intramuscular clodronate in long-term treatment of symptomatic knee osteoarthritis: a randomized controlled study”. Drugs in R&D 1 (2020): 39-45.
  30. R G Rosa., et al. “Clodronate exerts an anabolic effect on articular chondrocytes mediated through the purinergic receptor pathway”. Osteoarthritis and Cartilage9 (2014): 1327-1336.
  31. Nao Hasuzawa., et al. “Physiopathological roles of vesicular nucleotide transporter (VNUT), an essential component for vesicular ATP release”. Biochimica et Biophysica Acta (BBA) – Biomembranes 12 (2020): 183408.
  32. Thompson K., et al. “Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis”. Molecular Pharmacology 5 (2006): 1624-1632.
  33. Okada S., et al. “Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice”. Tohoku Journal of Experimental Medicine 2 (2013): 145-158.
  34. Lei He., et al. “Analysis and update of the human solute carrier (SLC) gene superfamily”. Human Genomics 2 (2009): 195-206.
  35. Hannu Mönkkönen., et al. “Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth”. Anticancer Drugs4 (2008): 391-399.
  36. Lehenkari PP., et al. “Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite”. Molecular Pharmacology 5 (2002): 1255-1262.
  37. Coxon FP., et al. “Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells”. Bone 5 (2008): 848-860.
  38. Hasuzawa N., et al. “Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury”. Scientific Reports 1 (2021): 5192.
  39. Tomoko Tokumaru., et al. “Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease”. Scientific Reports 1 (2024): 7813.
  40. Burnstock G and Novak I. “Purinergic signalling in the pancreas in health and disease”. Journal of Endocrinology 2 (2012): 123-141.
  41. Kenta Maruyama., et al. “The ATP transporter VNUT mediates induction of dectin-1-triggered Candida nociception”. iScience 6 (2018): 306-318.
  42. Mizuhara M., et al. “Vesicular nucleotide transporter mediates adenosine triphosphate release in compressed human periodontal ligament fibroblast cells and participates in tooth movement-induced nociception in rats”. Archives of Oral Biology 110 (2020): 104607.
  43. Mihara H., et al. “Transient receptor potential vanilloid 4 regulation of adenosine triphosphate release by the adenosine triphosphate transporter vesicular nucleotide transporter, a novel therapeutic target for gastrointestinal baroreception and chronic inflammation”. Digestion1 (2020): 6-11.
  44. Allavena P and Mantovani A. “Immunology in the clinic review series focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment”. Clinical and Experimental Immunology 2 (2012): 195-205.
  45. Nicole M Reusser., et al. “Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer”. Cancer Biology and Therapy 8 (2014): 1061-1067.
  46. Zhu J., et al. “Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis”. European Journal of Cancer 9 (2013): 2086-2092.
  47. Xiaobao Yang., et al. “Targeting proliferating tumor-infiltrating macrophages facilitates spatial redistribution of CD8+ T cells in pancreatic”. Cancers (Basel)6 (2022): 1474.
  48. Baek SH., et al. “Role of M2-like macrophages in the progression of ovarian cancer”. Experimental Cell Research 2 (2020): 112211.

Molfetta Luigi., et al. “The Secrets of Clodronate: An Old Drug with a New Soul”. EC Orthopaedics  16.5 (2025): 01-09.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net